Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- Lilly Joins Hands with NCC on Biomarkers for Advanced Gastric Cancer
March 28, 2016
- Global PIII for Xtandi Launched for Hormone Sensitive Prostate Cancer: Astellas
March 28, 2016
- Takashi Nakamura to Be Promoted to President of Qol
March 25, 2016
- Public Knowledge-Based Application Filed for Colchicine for Familial Mediterranean Fever
March 25, 2016
- MSD Going Full Out for Sakigake-Designated Pembrolizumab, Poised to Bolster Oncology Force
March 25, 2016
- Lilly Japan Logs 236 Billion Yen in 2015, Set to Further Boost Sales Force from 2,000
March 25, 2016
- Sosei Group Taps GSK Veteran Peter Bains as Next CEO
March 24, 2016
- Eisai Withdraws Japan NDA for Ultra-High Dose Mecobalamin for ALS
March 24, 2016
- Hengrui to Apply for Sakigake Designation; Develop New Drugs Alongside Generics in Japan
March 24, 2016
- Eisai to Return US Rights to Helsinn’s Antiemetic Akynzeo
March 23, 2016
- Valixa Filed for Prevention of CMV Disease in Organ Transplants: Mitsubishi Tanabe
March 23, 2016
- Romosozumab Yields Positive PIII Data in Male Osteoporosis: Amgen Astellas
March 23, 2016
- Higher Remission Rates in TNF Blocker-Naïve Patients Observed in Long-Term Vedolizumab Treatment
March 23, 2016
- Santen to Form JV with China’s Kerui for Generic Eye Drugs
March 23, 2016
- Opdivo Filed for Hodgkin’s Lymphoma in Japan
March 22, 2016
- Mochida to Codevelop Ajinomoto’s Oral Constipation Drug
March 22, 2016
- Jitsubo Aims to Launch Peptide Generic Drugs Using Its Unique Technologies
March 22, 2016
- Drug Makers Terminate Lysozyme, Pronase Sale after MHLW Panel Finds Them Ineffective
March 18, 2016
- Hisamitsu, Asahi Kasei End Sales Partnership for Neoxy Tape
March 18, 2016
- Meiji Seika Pharma, RIKEN Collaborate on Skin Regeneration Research
March 17, 2016
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…